Kirstin Spencer
@kjscello
Followers
101
Following
263
Media
20
Statuses
110
Teacher, Equestrian, Musician, Stage 4 Breast Cancer Patient Advocate.
Joined September 2021
RT @stage4kelly: @christeeny513 also addresses patient concerns about brain biopsy - especially after attending an earlier session which pr….
0
2
0
RT @stage4kelly: In talking about whole brain radiation in MBC brain mets @christeeny513 reminds the panel and audience that WBR, in additi….
0
3
0
RT @stage4kelly: Not forgetting those who are triple positive, adding ET and a CDK4/6 to HER2 targeted therapy provides benefit over just a….
0
1
0
RT @stage4kelly: Nick Turner sums up what we learned here about MBC, starting with EMBER3 #ESMOBreast25
0
6
0
RT @Dr_ElvinaA: 🔹 1L: AI or Fulv + CDK4/6i.🔹 2L:. • PI3K & ESR1 wt: Fulv + Everolimus / Abemaciclib. • ESR1 mut: Elacestrant. • PI3K mut: F….
0
60
0
RT @matteolambe: Proffered paper session at #ESMOBreast25 with @Prof_Nadia_H presenting the first results of #ADAPTcycle trial showing prel….
0
18
0
RT @METUPUKorg: The Darker Side of Pink Campaign is coming to Oxford!. Come see the interactive exhibition in Oxford at the Westgate Librar….
0
7
0
RT @FilippoMontemu1: ESR1 Y537S and D538G mutations drive resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer https….
pubmed.ncbi.nlm.nih.gov
We report herein real-world and preclinical evidence that ESR1 mutations, particularly Y537S and D538G, can drive resistance to CDK4/6i.
0
10
0
I’m taking part in Our Future Health. Join the UK’s largest health research programme:
0
0
1
American Association for Cancer Research Award winning Steffi Oesterreich gives an insightful and inspirational lecture about Lobular breast cancer. @lobularmoonshot .@LobularBCA.@LobularResearch .@ELBCAdvocates
0
0
1
RT @METUPUKorg: No one is counting Metastatic Breast Cancer patients in the UK. In 2022, a National Audit of Metastatic Breast Cancer (NAoM….
0
11
0
RT @ChristineDesme2: Obesity➡️ worse prognosis & different biology #breastcancer. Still, BMI is only reported in 8% of 495 trials we revie….
breast-cancer-research.biomedcentral.com
Background The proportion of patients with breast cancer and obesity is increasing. While the therapeutic landscape of breast cancer has been expanding, we lack knowledge about the potential differ...
0
15
0
RT @ChristineDesme2: Thanks a lot for the fantastic edition of the #ilcsymposium 2024 in Leuven! What an amazing community! Step by step mo….
0
14
0
Giampaolo Bianchini sums up MBC HER2 classifications for T-Dxd; IHC 0 assessments must be re-evaluated, one in four patients with local.IHC 0 are improperly denied access to a very effective treatment.#ESMO24.@METUPUKorg
0
1
4
Great talks on metastatic breast cancer oligometastatic bone, brain and leptomeningeal disease Biological rationale for local therapy of oligoprogressive disease…. #ESMO24.@METUPUKorg
0
3
5
Peter A. Fasching, “In the NATALEE breast cancer trial, a dose reduction of Ribociclib did not impact efficacy…”.#ESMO24.@METUPUKorg
1
2
4
Patricia Lorusso, “We need real time utilisation of Patient Reported Outcomes to aid clinical drug development”.
0
0
1
DESTINY Breast 04, DAISY and DESTINY Breast 06 confer HER-2 low status is clinically targetable with Enhertu and patients with HR+, HER2-ultralow mBC derived clinically meaningful benefit from Enhertu vs the Physicians choice. #ESMO24 .@METUPUKorg
1
2
8
ESMO Patient Advocacy Track; Sandrine Lavallé on Long Term .side effects; brain fog, cardio toxicity, bone thinning, bone loss, fatigue, menopause symptoms and… uncertainty #ESMO24.@METUPUKorg
0
2
7